Insulin modulates emotional behavior through a serotonin-dependent mechanism.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
07 Oct 2022
07 Oct 2022
Historique:
received:
22
12
2021
accepted:
21
09
2022
revised:
19
09
2022
entrez:
7
10
2022
pubmed:
8
10
2022
medline:
8
10
2022
Statut:
aheadofprint
Résumé
Type-2 Diabetes (T2D) is characterized by insulin resistance and accompanied by psychiatric comorbidities including major depressive disorders (MDD). Patients with T2D are twice more likely to suffer from MDD and clinical studies have shown that insulin resistance is positively correlated with the severity of depressive symptoms. However, the potential contribution of central insulin signaling in MDD in patients with T2D remains elusive. Here we hypothesized that insulin modulates the serotonergic (5-HT) system to control emotional behavior and that insulin resistance in 5-HT neurons contributes to the development of mood disorders in T2D. Our results show that insulin directly modulates the activity of dorsal raphe (DR) 5-HT neurons to dampen 5-HT neurotransmission through a 5-HT
Identifiants
pubmed: 36207585
doi: 10.1038/s41380-022-01812-3
pii: 10.1038/s41380-022-01812-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agence Nationale de la Recherche (French National Research Agency)
ID : ANR-18-CE14-0029
Organisme : Agence Nationale de la Recherche (French National Research Agency)
ID : ANR-17-CE14-0007
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24:1069–78.
pubmed: 11375373
doi: 10.2337/diacare.24.6.1069
Lee JH, Park SK, Ryoo JH, Oh CM, Mansur RB, Alfonsi JE, et al. The association between insulin resistance and depression in the Korean general population. J Affect Disord. 2017;208:553–9.
pubmed: 27810270
doi: 10.1016/j.jad.2016.10.027
Kan C, Silva N, Golden SH, Rajala U, Timonen M, Stahl D, et al. A systematic review and meta-analysis of the association between depression and insulin resistance. Diabetes Care. 2013;36:480–9.
pubmed: 23349152
pmcid: 3554272
doi: 10.2337/dc12-1442
Phillips CM, Perry IJ. Depressive symptoms, anxiety, and well-being among metabolic health obese subtypes. Psychoneuroendocrinology 2015;62:47–53.
pubmed: 26232649
doi: 10.1016/j.psyneuen.2015.07.168
Dutheil S, Ota KT, Wohleb ES, Rasmussen K, Duman RS. High-fat diet induced anxiety and anhedonia: impact on brain homeostasis and inflammation. Neuropsychopharmacology 2016;41:1874–87.
pubmed: 26658303
pmcid: 4869056
doi: 10.1038/npp.2015.357
Zemdegs J, Quesseveur G, Jarriault D, Pénicaud L, Fioramonti X, Guiard BP. High-fat diet-induced metabolic disorders impairs 5-HT function and anxiety-like behavior in mice. Br J Pharm. 2016;173:2095–110.
doi: 10.1111/bph.13343
Zemdegs J, Martin H, Pintana H, Bullich S, Manta S, Marqués MA, et al. Metformin promotes anxiolytic and antidepressant-like responses in insulin-resistant mice by decreasing circulating branched-chain amino acids. J Neurosci. 2019;39:5935–48.
pubmed: 31160539
pmcid: 6650994
doi: 10.1523/JNEUROSCI.2904-18.2019
Hassan AM, Mancano G, Kashofer K, Fröhlich EE, Matak A, Mayerhofer R, et al. High-fat diet induces depression-like behaviour in mice associated with changes in microbiome, neuropeptide Y, and brain metabolome. Nutr Neurosci. 2019;22:877–93.
pubmed: 29697017
doi: 10.1080/1028415X.2018.1465713
Papazoglou IK, Jean A, Gertler A, Taouis M, Vacher CM. Hippocampal GSK3β as a molecular link between obesity and depression. Mol Neurobiol. 2015;52:363–74.
pubmed: 25169083
doi: 10.1007/s12035-014-8863-x
Martin H, Bullich S, Guiard BP, Fioramonti X. The impact of insulin on the serotonergic system and consequences on diabetes-associated mood disorders. J Neuroendocrinol. 2021;33:e12928.
pubmed: 33506507
doi: 10.1111/jne.12928
Kleinridders A, Cai W, Cappellucci L, Ghazarian A, Collins WR, Vienberg SG, et al. Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc Natl Acad Sci. 2015;112:3463–8.
pubmed: 25733901
pmcid: 4371978
doi: 10.1073/pnas.1500877112
Guiard BP, El Mansari M, Blier P. Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors. Curr Drug Targets. 2009;10:1069–84.
pubmed: 19702555
doi: 10.2174/138945009789735156
Labouèbe G, Liu S, Dias C, Zou H, Wong JCY, Karunakaran S, et al. Insulin induces long-term depression of VTA dopamine neurons via an endocannabinoid-mediated mechanism. Nat Neurosci. 2013;16:300–8.
pubmed: 23354329
pmcid: 4072656
doi: 10.1038/nn.3321
Könner AC, Hess S, Tovar S, Mesaros A, Sánchez-Lasheras C, Evers N, et al. Role for insulin signaling in catecholaminergic neurons in control of energy homeostasis. Cell Metab. 2011;13:720–8.
pubmed: 21641553
doi: 10.1016/j.cmet.2011.03.021
Evans MC, Kumar NS, Inglis MA, Anderson GM. Leptin and insulin do not exert redundant control of metabolic or emotive function via dopamine neurons. Horm Behav. 2018;106:93–104.
pubmed: 30292429
doi: 10.1016/j.yhbeh.2018.10.001
Yohn CN, Gergues MM, Samuels BA. The role of 5-HT receptors in depression. Mol Brain. 2017;10:28.
pubmed: 28646910
pmcid: 5483313
doi: 10.1186/s13041-017-0306-y
Kiyasova V, Fernandez SP, Laine J, Stankovski L, Muzerelle A, Doly S, et al. A genetically defined morphologically and functionally unique subset of 5-HT neurons in the mouse raphe nuclei. J Neurosci J Soc Neurosci. 2011;31:2756–68.
doi: 10.1523/JNEUROSCI.4080-10.2011
Hanson LR, Fine JM, Svitak AL, Faltesek KA, Intranasal administration of CNS therapeutics to awake mice. J Vis Exp. 2013;74:4440.
Dhuria SV, Hanson LR, Frey WH. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010;99:1654–73.
pubmed: 19877171
doi: 10.1002/jps.21924
Fan LW, Carter K, Bhatt A, Pang Y. Rapid transport of insulin to the brain following intranasal administration in rats. Neural Regen Res. 2019;14:1046–51.
pubmed: 30762017
pmcid: 6404510
doi: 10.4103/1673-5374.250624
Dellu-Hagedorn F, Fitoussi A, De Deurwaerdère P. Correlative analysis of dopaminergic and serotonergic metabolism across the brain to study monoaminergic function and interaction. J Neurosci Methods. 2017;280:54–63.
pubmed: 28161298
doi: 10.1016/j.jneumeth.2017.01.020
Puginier E, Bharatiya R, Chagraoui A, Manem J, Cho YH, Garret M, et al. Early neurochemical modifications of monoaminergic systems in the R6/1 mouse model of Huntington’s disease. Neurochem Int. 2019;128:186–95.
pubmed: 31054882
doi: 10.1016/j.neuint.2019.05.001
Rainer Q, Nguyen HT, Quesseveur G, Gardier AM, David DJ, Guiard BP. Functional status of somatodendritic serotonin 1A autoreceptor after long-term treatment with fluoxetine in a mouse model of anxiety/depression based on repeated corticosterone administration. Mol Pharm. 2012;81:106–12.
doi: 10.1124/mol.111.075796
Qesseveur G, Petit AC, Nguyen HT, Dahan L, Colle R, Rotenberg S, et al. Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach. Neuropharmacology 2016;105:142–53.
pubmed: 26764241
doi: 10.1016/j.neuropharm.2015.12.022
Guiard BP, Przybylski C, Guilloux JP, Seif I, Froger N, De Felipe C, et al. Blockade of substance P (neurokinin 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. J Neurochem. 2004;89:54–63.
pubmed: 15030389
doi: 10.1046/j.1471-4159.2003.02304.x
Ferreira de Sá DS, Römer S, Brückner AH, Issler T, Hauck A, Michael T. Effects of intranasal insulin as an enhancer of fear extinction: a randomized, double-blind, placebo-controlled experimental study. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2020;45:753–60.
doi: 10.1038/s41386-019-0593-3
Marks DR, Tucker K, Cavallin MA, Mast TG, Fadool DA. Awake intranasal insulin delivery modifies protein complexes and alters memory, anxiety, and olfactory behaviors. J Neurosci. 2009;29:6734–51.
pubmed: 19458242
pmcid: 2779219
doi: 10.1523/JNEUROSCI.1350-09.2009
Schmid V, Kullmann S, Gfrörer W, Hund V, Hallschmid M, Lipp HP, et al. Safety of intranasal human insulin: A review. Diabetes Obes Metab. 2018;20:1563–77.
pubmed: 29508509
doi: 10.1111/dom.13279
Papazoglou I, Berthou F, Vicaire N, Rouch C, Markaki EM, Bailbe D, et al. Hypothalamic serotonin–insulin signaling cross-talk and alterations in a type 2 diabetic model. Mol Cell Endocrinol. 2012;350:136–44.
pubmed: 22209745
doi: 10.1016/j.mce.2011.12.007
Portal B, Delcourte S, Rovera R, Lejards C, Bullich S, Malnou CE, et al. Genetic and pharmacological inactivation of astroglial connexin 43 differentially influences the acute response of antidepressant and anxiolytic drugs. Acta Physiol Oxf Engl. 2020;229:e13440.
MacKenzie RG, Trulson ME. Effects of insulin and streptozotocin-induced diabetes on brain tryptophan and serotonin metabolism in rats. J Neurochem. 1978;30:205–11.
pubmed: 621508
doi: 10.1111/j.1471-4159.1978.tb07053.x
Orosco M, Nicolaidis S. Insulin and glucose-induced changes in feeding and medial hypothalamic monoamines revealed by microdialysis in rats. Brain Res Bull. 1994;33:289–97.
pubmed: 8293313
doi: 10.1016/0361-9230(94)90196-1
Martín-Cora FJ, Fornal CA, Metzler CW, Jacobs BL. Insulin-induced hypoglycemia decreases single-unit activity of serotonergic medullary raphe neurons in freely moving cats: relationship to sympathetic and motor output: Medullary 5-HT neuronal responses to glucoregulatory challenges. Eur J Neurosci. 2002;16:722–34.
pubmed: 12270048
doi: 10.1046/j.1460-9568.2002.02144.x
Chaput Y, de Montigny C, Blier P. Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn Schmiedebergs Arch Pharm. 1986;333:342–8.
doi: 10.1007/BF00500007
Czachura JF, Rasmussen K. Effects of acute and chronic administration of fluoxetine on the activity of serotonergic neurons in the dorsal raphe nucleus of the rat. Naunyn Schmiedebergs Arch Pharm. 2000;362:266–75.
doi: 10.1007/s002100000290
Bosker FJ, Klompmakers A, Westenberg HGM. Postsynaptic 5-HT1A receptors mediate 5-hydroxytryptamine release in the amygdala through a feedback to the caudal linear raphe. Eur J Pharm. 1997;333:147–57.
doi: 10.1016/S0014-2999(97)01141-2
Martín-Ruiz R, Ugedo L. Electrophysiological evidence for postsynaptic 5-HT(1A) receptor control of dorsal raphe 5-HT neurones. Neuropharmacology 2001;41:72–8.
pubmed: 11445187
doi: 10.1016/S0028-3908(01)00050-8
Hajós M, Richards CD, Székely AD, Sharp T. An electrophysiological and neuroanatomical study of the medial prefrontal cortical projection to the midbrain raphe nuclei in the rat. Neuroscience 1998;87:95–108.
pubmed: 9722144
doi: 10.1016/S0306-4522(98)00157-2
Craven R, Grahame-Smith D, Newberry N. WAY-100635 and GR127935: effects on 5-hydroxytryptamine-containing neurones. Eur J Pharm. 1994;271:R1–3.
doi: 10.1016/0014-2999(94)90289-5
Fletcher A, Forster EA, Bill DJ, Brown G, Cliffe IA, Hartley JE, et al. Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav Brain Res. 1996;73:337–53.
pubmed: 8788530
doi: 10.1016/0166-4328(96)00118-0
Johnson DA, Gartside SE, Ingram CD. 5-HT1A receptor-mediated autoinhibition does not function at physiological firing rates: evidence from in vitro electrophysiological studies in the rat dorsal raphe nucleus. Neuropharmacology 2002;43:959–65.
pubmed: 12423665
doi: 10.1016/S0028-3908(02)00116-8
Deryabina IB, Andrianov VV, Muranova LN, Bogodvid TK, Gainutdinov KL, Effects of thryptophan hydroxylase blockade by P-Chlorophenylalanine on contextual memory reconsolidation after training of different intensity. Int J Mol Sci. 2020;21:2087.
Johnson PL, Molosh A, Fitz SD, Arendt D, Deehan GA, Federici LM, et al. Pharmacological depletion of serotonin in the basolateral amygdala complex reduces anxiety and disrupts fear conditioning. Pharm Biochem Behav. 2015;138:174–9.
doi: 10.1016/j.pbb.2015.09.021
Engin E, Smith KS, Gao Y, Nagy D, Foster RA, Tsvetkov E, et al. Modulation of anxiety and fear via distinct intrahippocampal circuits. eLife 2016;5:e14120.
pubmed: 26971710
pmcid: 4816644
doi: 10.7554/eLife.14120
Wagle M, Zarei M, Lovett-Barron M, Poston KT, Xu J, Ramey V, et al. Brain-wide perception of the emotional valence of light is regulated by distinct hypothalamic neurons. Mol Psychiatry. 2022;1–17. Online ahead of print.
Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167:748–51.
pubmed: 20595427
doi: 10.1176/appi.ajp.2010.09091379
Sharma S, Fulton S. Diet-induced obesity promotes depressive-like behaviour that is associated with neural adaptations in brain reward circuitry. Int J Obes. 2013;37:382.
doi: 10.1038/ijo.2012.48
Liu Z, Patil IY, Jiang T, Sancheti H, Walsh JP, Stiles BL, et al. High-fat diet induces hepatic insulin resistance and impairment of synaptic plasticity. PloS One. 2015;10:e0128274.
pubmed: 26023930
pmcid: 4449222
doi: 10.1371/journal.pone.0128274
Kothari V, Luo Y, Tornabene T, O’Neill AM, Greene MW, Geetha T, et al. High-fat diet induces brain insulin resistance and cognitive impairment in mice. Biochim Biophys Acta Mol Basis Dis. 2017;1863:499–508.
pubmed: 27771511
doi: 10.1016/j.bbadis.2016.10.006
Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry. 2006;163:28–40.
pubmed: 16390886
doi: 10.1176/appi.ajp.163.1.28
Blier P, Ward H. Toward optimal treatments for major depression. CNS Spectr. 2002;7:148–50. 153–4
pubmed: 15220857
doi: 10.1017/S1092852900017466
Poggini S, Golia MT, Alboni S, Milior G, Sciarria LP, Viglione A, et al. Combined fluoxetine and metformin treatment potentiates antidepressant efficacy increasing IGF2 expression in the dorsal hippocampus. Neural Plast. 2019;2019:1–12.
doi: 10.1155/2019/4651031